iECURE, a gene-editing company spun out of Penn and co-founded by Dr. James Wilson, the Rose H. Weiss Orphan Disease Center Director’s Professor at Penn Medicine, has received three special designations from the FDA for ECUR-506, a novel treatment being developed for newborns with Ornithine transcarbamylase (OTC) deficiency, a rare liver disorder. These designations support the development of treatments for rare conditions and could speed up the approval process for ECUR-506. The company plans to treat its first patient in a clinical trial this year. Read more here.